Synergia Energy's Cambay PSC Sale Agreement Collapses as Selan Fails to Meet Conditions

Cambay PSC sale stalls as Selan misses bank guarantee deadline

Synergia Energy’s proposed sale of its 50% working interest in the Cambay Production Sharing Contract (PSC) in India has hit the buffers. The buyer, Antelopus Selan Energy Limited, failed to deliver a required bank guarantee for the deferred payment tranche before the 8 February exclusivity cut-off. As a result, Synergia says it will now examine its options. The company remains willing to complete the deal, but the conditions precedent were not satisfied in time.

There is a small consolation: a non-refundable US$0.5 million already paid by Selan will be retained if the sale does not close.

What Synergia actually announced

On 1 December 2025, Synergia signed a Sale and Purchase Agreement (SPA) with Selan for total consideration of up to US$14 million in two tranches. Synergia’s shareholders approved the transaction on 29 December 2025. However, Selan did not provide the bank guarantee backing the deferred payment. Selan cited a refusal by its major shareholder, Oak Tree Capital, to sanction completion.

Exclusivity under the Heads of Terms, signed on 4 July 2025, expired on 8 February 2026. With that window closed, Synergia intends to weigh alternatives. Meanwhile, the parties remain bound by a previously executed Farm-In/Farm-Out Agreement, including an agreed work programme to drill three new Eocene wells at Cambay.

Key numbers and milestones

Asset	Cambay PSC, onshore India
Synergia working interest	50%
SPA total consideration	Up to US$14 million (two tranches)
Shareholder approval	29 December 2025
Exclusivity period end	8 February 2026
Non-refundable payment retained	US$0.5 million
Stated reserves metric	206 BCF P50 Eocene gas
Work commitments	Drilling three new Eocene wells under Farm-In/Farm-Out

Why the bank guarantee mattered

The bank guarantee is standard in staged deals. It secures the deferred consideration, protecting the seller if the buyer later defaults. Without it, Synergia would be taking on counterparty risk for a material chunk of the US$14 million headline price. Selan’s failure to provide the guarantee, reportedly due to a block from its major shareholder, is a clear red flag on deal certainty.

For investors, this underlines the importance of financing certainty in SPA conditions precedent. No guarantee, no comfort that the money shows up on time.

Exclusivity has lapsed – Synergia can now explore alternatives

With exclusivity expired, Synergia is no longer tied to Selan. The company says it will examine its options. That could include re-engaging with other interested parties, renegotiating structure and security, or simply proceeding with the existing Farm-In/Farm-Out work programme. The RNS does not disclose any timeline or alternative counterparties.

Importantly, the US$0.5 million paid by Selan under the Heads of Terms is non-refundable if the SPA does not close, providing some compensation for the prolonged process.

Cambay PSC fundamentals still front and centre

CEO Roland Wessel highlighted the “inherent value” of Cambay’s 206 BCF P50 Eocene gas. P50 denotes the mid case estimate – a 50% probability of at least that volume being recoverable. The RNS also emphasises that the Farm-In/Farm-Out Agreement remains in force, including the obligation to drill three new Eocene wells.

If executed well, those wells could be value catalysts, but the RNS does not provide schedules, funding details, or operational plans. Investors should watch for a firm programme and approvals to de-risk timelines.

What could happen next

• Re-open the process: With exclusivity over, Synergia can test the market for new bids or farm-outs. Price, structure, and security will be key.
• Renegotiate with Selan: Synergia says it remains willing to complete. If Selan can line up the bank guarantee, a closing could still be resurrected, but there is no commitment or timetable disclosed.
• Push ahead with drilling: The Farm-In/Farm-Out Agreement binds the parties to three new Eocene wells. Execution and funding detail are not disclosed, so look for an operational update.

There is no mention of cash position, capex budgets, or regulatory steps in this RNS. Those items will determine pace and risk.

Positives and negatives in plain sight

What looks positive

• US$0.5 million non-refundable payment retained – a tangible offset to deal slippage.
• Asset quality signal – management reiterates belief in 206 BCF P50 Eocene gas, with three wells mandated under the Farm-In/Farm-Out.
• Optionality restored – with exclusivity gone, Synergia can seek better terms or more credible counterparties.

What gives pause

• Deal uncertainty – headline US$14 million proceeds now look unlikely near term without the guarantee.
• Counterparty risk exposed – a major shareholder veto at the buyer scuppered conditions precedent.
• Execution questions – drilling obligations exist, but timing, funding and operational detail are not disclosed.

Jargon buster

• SPA (Sale and Purchase Agreement): The binding contract to sell the asset, subject to conditions precedent such as approvals and financing.
• Bank guarantee: A bank’s promise to pay if the buyer does not, securing deferred consideration.
• P50: The mid case reserves or resources estimate with a 50% probability of being met or exceeded.
• Farm-In/Farm-Out: An agreement where one party earns into a project by funding work, such as drilling, in exchange for an interest.
• PSC (Production Sharing Contract): An arrangement with a government where the contractor recovers costs and shares production per contract terms.

My take for AIM investors

This update is disappointing for anyone banking on quick cash proceeds, but it is not the end of the story. Synergia keeps the US$0.5 million and the door is open to new bidders or a reworked deal, while the binding work programme means Cambay activity is still on the cards.

Near term, expect the focus to shift to two things: clarity on the drilling timetable for the three Eocene wells and whether Synergia can secure a new transaction with firmer financing. Until those arrive, uncertainty lingers, but the company is signalling confidence in Cambay’s scale and is no longer tied to a single counterparty.

Bottom line: proceeds are delayed, not dead. Watch for updates on counterparties, guarantees, and spud dates. The next RNS on funding and schedules will be pivotal.